MorphoSys Grants ImmunoGen Access to HuCAL GOLD®
MorphoSys AG announced that the US biotechnology company, ImmunoGen Inc., has licensed access to the MorphoSys HuCAL GOLD® library for use in ImmunoGen's internal target research programs. ImmunoGen will pay MorphoSys subscription fees during the one-year term of the agreement. Further financial details were not disclosed.
In June 2001, ImmunoGen and MorphoSys entered into a collaboration to use MorphoSys's previous version of the HuCAL® library (Human Combinatorial Antibody Library) in ImmunoGen's internal research programs. The four-year term of this prior agreement ended in May 2005.
The two companies also have a separate collaboration, established in September 2000, to develop a fully human antibody against an ImmunoGen-provided cell-surface target associated with various forms of cancer.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Adipose Stem & Regenerative Cells Not Linked to Arrhythmias in Preclinical Study - Important Safety Findings Published in EuroPace Cardiology Journal
Researchers create 'leukemia in a dish' to better study it

Circular RNA makes fruit flies live longer - One step closer to the mysterious circRNAs

Accreditation to an International Standard - IS015189
Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
Stanford University Licenses Ingenuity Pathways Analysis, Collaborates on Systems Biology Solutions - Stanford Genome Technology Center Will apply Ingenuity's technology to More Quickly and Comprehensively Understand the Biology Underlying Their Experimental Datasets
